New Fat-Melting injection for double chin enters human testing
NCT ID NCT06756490
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called HY-2003, a fat-dissolving injection for people with moderate to severe double chin. About 30 adults will receive either HY-2003, an existing treatment (BELKYRA), or a placebo. The main goal is to check safety, but researchers will also look at how well it reduces chin fat.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposome-encapsulated deoxycholic acid (HY-2003)
- What this could lead to
- If successful, this could offer a new injectable option for reducing double chin fat with potentially fewer side effects than current treatments.
- What could go wrong
- This is an early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. The treatment may cause injection-site reactions or fail to reduce fat better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE OR SEVERE SUBMENTAL FULLNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi'an, Shaanxi, 710061, China